Literature DB >> 32606157

Association Between HMGB1 and Thrombogenesis in a Hyperlipaemia-induced Microminipig Model of Atherosclerosis.

Satoru Kake1,2, Hiroaki Kawaguchi3, Tomoka Nagasato4,5, Tomonobu Yamada6, Takashi Ito4, Ikuro Maruyama4, Naoki Miura7, Akihide Tanimoto8.   

Abstract

BACKGROUND/AIM: An appropriate animal model is essential to investigate the relationship between inflammation, atherosclerosis, and thrombogenesis, and the development of preventive measures and therapies for atherosclerosis.
MATERIALS AND METHODS: Atherosclerosis was induced in Microminipigs (MMPs) using a high-fat diet. We assessed high mobility group box 1 (HMGB1) expression levels and measured thrombus formation using a Total Thrombus Formation Analysis System (T-TAS). MMPs were divided into a normal diet (control) group and four high-fat diet groups, with differing amounts of cholesterol. After 8 weeks, blood was collected for analysis.
RESULTS: HMGB1 levels increased with increasing dietary cholesterol, and a negative correlation was found between HMGB1 levels and thrombus formation time.
CONCLUSION: T-TAS is useful in the assessment of thrombogenesis in MMPs and HMGB1 is associated with thrombus formation. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  HMGB1; Microminipig; thrombus formation

Mesh:

Substances:

Year:  2020        PMID: 32606157      PMCID: PMC7439884          DOI: 10.21873/invivo.11982

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  21 in total

Review 1.  Alarmin(g) news about danger: workshop on innate danger signals and HMGB1.

Authors:  Helena Erlandsson Harris; Angela Raucci
Journal:  EMBO Rep       Date:  2006-07-21       Impact factor: 8.807

Review 2.  HMGB1 as a DNA-binding cytokine.

Authors:  Ulf Andersson; Helena Erlandsson-Harris; Huan Yang; Kevin J Tracey
Journal:  J Leukoc Biol       Date:  2002-12       Impact factor: 4.962

3.  Arterial endothelial function in a porcine model of early stage atherosclerotic vascular disease.

Authors:  James R Turk; Kyle K Henderson; Gregory D Vanvickle; Justin Watkins; M Harold Laughlin
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

Review 4.  Plaque rupture in humans and mice.

Authors:  Stephen M Schwartz; Zorina S Galis; Michael E Rosenfeld; Erling Falk
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-03-01       Impact factor: 8.311

5.  Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation.

Authors:  T Ito; I Maruyama
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

6.  Cell compositions of coronary and aortic atherosclerotic lesions in WHHL rabbits differ. An immunohistochemical study.

Authors:  M Shiomi; T Ito; T Tsukada; T Yata; M Ueda
Journal:  Arterioscler Thromb       Date:  1994-06

Review 7.  Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review.

Authors:  Ben Lu; Ce Wang; Mao Wang; Wei Li; Fangping Chen; Kevin J Tracey; Haichao Wang
Journal:  Expert Rev Clin Immunol       Date:  2014-04-19       Impact factor: 4.473

8.  Coagulation activity and white thrombus formation in the microminipig.

Authors:  Naoki Miura; Hiroaki Kawaguchi; Tomoka Nagasato; Tomonobu Yamada; Takashi Ito; Hiroyuki Izumi; Hisayo Shameshima; Noriaki Miyoshi; Akihide Tanimoto; Ikuro Maruyama
Journal:  In Vivo       Date:  2013 May-Jun       Impact factor: 2.155

9.  Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines.

Authors:  N Kalinina; A Agrotis; Y Antropova; G DiVitto; P Kanellakis; G Kostolias; O Ilyinskaya; E Tararak; A Bobik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-16       Impact factor: 8.311

Review 10.  Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function.

Authors:  S Müller; L Ronfani; M E Bianchi
Journal:  J Intern Med       Date:  2004-03       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.